• Beyond Visualization: Scientific Impact of Triple Color Prot

  2026-06-13

  Explore the molecular precision and advanced compatibility of the Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa). This in-depth article reveals its scientific advantages for SDS-PAGE and Western blotting, with unique insights on assay design and translational research.

• JNK-IN-7: Selective JNK Inhibitor for MAPK Pathway Research

  2026-06-12

  JNK-IN-7 empowers researchers to dissect apoptosis and innate immune signaling with unprecedented selectivity and workflow precision. Leverage this covalent JNK inhibitor for robust, reproducible MAPK pathway studies—especially where pathway crosstalk and inflammation mechanisms are under scrutiny.

• E-64d for Cysteine Protease Inhibition: Workflows & Troubles

  2026-06-12

  E-64d (ethyl (2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate) delivers robust, membrane-permeable inhibition of calpain and cathepsins for apoptosis, platelet, and neuroprotection assays. This guide details optimized protocols, comparative advantages, and troubleshooting strategies, leveraging recent discoveries in lysosome-dependent cell death.

• Tacrolimus (FK506) in Immune Signaling: Protocols & Pitfalls

  2026-06-11

  Tacrolimus (FK506) stands out as a gold-standard tool for precise modulation of T-cell activation and cytokine signaling in advanced immunology research. This article delivers hands-on workflows, troubleshooting insights, and lessons from cutting-edge studies, positioning APExBIO's FK506 as a cornerstone for reliable, reproducible immune response experiments.

• mRNA Nanovaccines Target Neutrophils to Boost Liver Cancer I

  2026-06-11

  A recent study introduces a biomimetic mRNA nanovaccine platform engineered to specifically target and activate tumor-associated neutrophils in hepatocellular carcinoma. By leveraging CD300LD-coated liposomes and IL-36γ mRNA payloads, the approach achieves heightened anti-tumor immune responses and significantly improves survival outcomes, offering a new paradigm in neutrophil-directed immunotherapy.

• Prevotella copri Depletes Host IPA, Enhancing Breast Cancer

  2026-06-10

  This study uncovers how Prevotella copri, a gut microbe enriched in breast cancer patients, depletes host indole-3-pyruvic acid (IPA), thereby promoting tumor progression through negative regulation of AMPK via UHRF1. These findings provide mechanistic insight into microbiome-driven cancer risk and identify IPA as a potential anti-cancer metabolite.

• Quantifying HBV Resistance: Systematic Review of Entecavir D

  2026-06-10

  This systematic review and meta-analysis provides the first pooled estimates of hepatitis B virus (HBV) resistance rates to entecavir and tenofovir, using data from over 12,000 individuals across 62 studies. The findings highlight low but rising entecavir resistance in treatment-naïve patients, and a substantial resistance risk in nucleos(t)ide-experienced groups, emphasizing the importance of robust surveillance and informed therapeutic strategies.

• Mildronate-Derived Lipidoids for Safer, Efficient mRNA Vacci

  2026-06-09

  The referenced ACS Nano study introduces mildronate-derived cationic lipidoids as an innovative alternative to standard ionizable lipids in mRNA lipid nanoparticles, achieving high delivery efficiency with significantly reduced inflammatory responses in preclinical melanoma models. These advances have important implications for developing safer mRNA vaccines and immunotherapeutics.

• Cyclosporin A: Optimizing T-cell Inhibition & Mitochondrial

  2026-06-09

  Cyclosporin A, the gold-standard immunosuppressive cyclic undecapeptide, is indispensable for dissecting T-cell activation and mitochondrial function. This article delivers advanced workflow enhancements, troubleshooting strategies, and actionable insights to elevate your immunology and mitochondrial research with APExBIO’s Cyclosporin.

• High-Concentration Lipid Nanoparticles Enhance mRNA Delivery

  2026-06-08

  The referenced study demonstrates that increasing lipid mixture concentrations in lipid nanoparticle (LNP) formulations preserves particle characteristics while significantly boosting in vivo gene expression and storage stability. These findings offer a scalable pathway for improving mRNA-LNP therapeutics and provide actionable insights for optimizing bioluminescent reporter assays and other mRNA applications.

• Magnetic Stimulation and GABAA ε Subunit Modulation in Schiz

  2026-06-08

  This study demonstrates that precise magnetic stimulation of the left prelimbic cortex downregulates the GABAA receptor epsilon subunit, alleviating schizophrenia-like behaviors and synaptic deficits in mice. The findings clarify molecular mechanisms underlying noninvasive brain stimulation and highlight new therapeutic targets for schizophrenia research.

• ARCA Cy5 EGFP mRNA (5-moUTP): Optimizing mRNA Delivery Analy

  2026-06-07

  ARCA Cy5 EGFP mRNA (5-moUTP) empowers researchers to directly visualize and quantify mRNA delivery, localization, and translation in mammalian cells using dual fluorescence. Its immune-evasive modifications and stability enhancements make it a superior tool for troubleshooting and refining mRNA transfection workflows across research and translational pipelines.

• CTP Solution (100 mM): Molecular Basis for Precision RNA Syn

  2026-06-06

  Explore the scientific foundation and advanced use of CTP Solution (100 mM) as a high-fidelity substrate for RNA synthesis, focusing on its essential role in modern mRNA therapeutics. This article delivers unique mechanistic insights and protocol guidance for researchers optimizing in vitro transcription.

• Brassinolide (A3265): Structure, Bioactivity, and Research U

  2026-06-05

  Brassinolide is a key plant sterol and growth regulator with robust, cross-domain research applications. Mechanistically, it induces apoptosis in PC-3 prostate cancer cells and lowers blood glucose in diabetic rat models. Its activity as a plant growth promoter is well-characterized and benchmarked against synthetic analogs.

• CD28–ARS2 Axis Drives PKM2 Splicing and CD8+ T Cell Antitumo

  2026-06-05

  This study uncovers a novel mechanism by which the CD28–ARS2 signaling axis orchestrates alternative splicing of pyruvate kinase (PKM), promoting PKM2 expression and enhancing the metabolic flexibility and effector function of CD8+ T cells. These findings have significant implications for immunometabolic research and the development of strategies targeting T cell-mediated antitumor responses.

454 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page